Literature DB >> 26150605

The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

Emilie Cornec-Le Gall1, Marie-Pierre Audrézet2, Annick Rousseau3, Maryvonne Hourmant4, Eric Renaudineau5, Christophe Charasse6, Marie-Pascale Morin7, Marie-Christine Moal8, Jacques Dantal4, Bassem Wehbe9, Régine Perrichot10, Thierry Frouget7, Cécile Vigneau7, Jérôme Potier6, Philippe Jousset11, Marie-Paule Guillodo12, Pascale Siohan9, Nazim Terki13, Théophile Sawadogo14, Didier Legrand15, Victorio Menoyo-Calonge16, Seddik Benarbia17, Dominique Besnier18, Hélène Longuet19, Claude Férec20, Yannick Le Meur21.   

Abstract

The course of autosomal dominant polycystic kidney disease (ADPKD) varies among individuals, with some reaching ESRD before 40 years of age and others never requiring RRT. In this study, we developed a prognostic model to predict renal outcomes in patients with ADPKD on the basis of genetic and clinical data. We conducted a cross-sectional study of 1341 patients from the Genkyst cohort and evaluated the influence of clinical and genetic factors on renal survival. Multivariate survival analysis identified four variables that were significantly associated with age at ESRD onset, and a scoring system from 0 to 9 was developed as follows: being male: 1 point; hypertension before 35 years of age: 2 points; first urologic event before 35 years of age: 2 points; PKD2 mutation: 0 points; nontruncating PKD1 mutation: 2 points; and truncating PKD1 mutation: 4 points. Three risk categories were subsequently defined as low risk (0-3 points), intermediate risk (4-6 points), and high risk (7-9 points) of progression to ESRD, with corresponding median ages for ESRD onset of 70.6, 56.9, and 49 years, respectively. Whereas a score ≤3 eliminates evolution to ESRD before 60 years of age with a negative predictive value of 81.4%, a score >6 forecasts ESRD onset before 60 years of age with a positive predictive value of 90.9%. This new prognostic score accurately predicts renal outcomes in patients with ADPKD and may enable the personalization of therapeutic management of ADPKD.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  ADPKD; end-stage renal disease; genetic renal disease; progression of renal failure; risk factors

Mesh:

Substances:

Year:  2015        PMID: 26150605      PMCID: PMC4769200          DOI: 10.1681/ASN.2015010016

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  24 in total

1.  Survival model predictive accuracy and ROC curves.

Authors:  Patrick J Heagerty; Yingye Zheng
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

Review 2.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

Review 3.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

4.  Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Authors:  María V Irazabal; Laureano J Rangel; Eric J Bergstralh; Sara L Osborn; Amber J Harmon; Jamie L Sundsbak; Kyongtae T Bae; Arlene B Chapman; Jared J Grantham; Michal Mrug; Marie C Hogan; Ziad M El-Zoghby; Peter C Harris; Bradley J Erickson; Bernard F King; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 10.121

5.  Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients.

Authors:  R Torra; C Badenas; L Pérez-Oller; J Luis; S Millán; C Nicolau; F Oppenheimer; M Milà; A Darnell
Journal:  Am J Kidney Dis       Date:  2000-10       Impact factor: 8.860

6.  Volume progression in polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres; Arlene B Chapman; Lisa M Guay-Woodford; Kyongtae T Bae; Bernard F King; Louis H Wetzel; Deborah A Baumgarten; Phillip J Kenney; Peter C Harris; Saulo Klahr; William M Bennett; Gladys N Hirschman; Catherine M Meyers; Xiaoling Zhang; Fang Zhu; John P Miller
Journal:  N Engl J Med       Date:  2006-05-18       Impact factor: 91.245

7.  Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease.

Authors:  A M Johnson; P A Gabow
Journal:  J Am Soc Nephrol       Date:  1997-10       Impact factor: 10.121

8.  Childhood onset autosomal dominant polycystic kidney disease in sibs: clinical picture and recurrence risk. German Working Group on Paediatric Nephrology (Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors:  K Zerres; S Rudnik-Schöneborn; F Deget
Journal:  J Med Genet       Date:  1993-07       Impact factor: 6.318

9.  Unified criteria for ultrasonographic diagnosis of ADPKD.

Authors:  York Pei; James Obaji; Annie Dupuis; Andrew D Paterson; Riccardo Magistroni; Elizabeth Dicks; Patrick Parfrey; Benvon Cramer; Eliecer Coto; Roser Torra; Jose L San Millan; Robert Gibson; Martijn Breuning; Dorien Peters; David Ravine
Journal:  J Am Soc Nephrol       Date:  2008-10-22       Impact factor: 10.121

10.  Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.

Authors:  Sandro Rossetti; Mark B Consugar; Arlene B Chapman; Vicente E Torres; Lisa M Guay-Woodford; Jared J Grantham; William M Bennett; Catherine M Meyers; Denise L Walker; Kyongtae Bae; Qin Jean Zhang; Paul A Thompson; J Philip Miller; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2007-06-20       Impact factor: 10.121

View more
  102 in total

1.  Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

Authors:  Matteo Bargagli; Nasser A Dhayat; Manuel Anderegg; Mariam Semmo; Uyen Huynh-Do; Bruno Vogt; Pietro Manuel Ferraro; Daniel G Fuster
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 8.237

2.  Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.

Authors:  Emilie Cornec-Le Gall; Rory J Olson; Whitney Besse; Christina M Heyer; Vladimir G Gainullin; Jessica M Smith; Marie-Pierre Audrézet; Katharina Hopp; Binu Porath; Beili Shi; Saurabh Baheti; Sarah R Senum; Jennifer Arroyo; Charles D Madsen; Claude Férec; Dominique Joly; François Jouret; Oussamah Fikri-Benbrahim; Christophe Charasse; Jean-Marie Coulibaly; Alan S Yu; Korosh Khalili; York Pei; Stefan Somlo; Yannick Le Meur; Vicente E Torres; Peter C Harris
Journal:  Am J Hum Genet       Date:  2018-04-26       Impact factor: 11.025

3.  Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Salim S Hayek; Douglas P Landsittel; Changli Wei; Martin Zeier; Alan S L Yu; Vicente E Torres; Sharin Roth; Christina S Pao; Jochen Reiser
Journal:  J Am Soc Nephrol       Date:  2019-06-06       Impact factor: 10.121

4.  The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.

Authors:  Sravanthi Lavu; Lisa E Vaughan; Sarah R Senum; Timothy L Kline; Arlene B Chapman; Ronald D Perrone; Michal Mrug; William E Braun; Theodore I Steinman; Frederic F Rahbari-Oskoui; Godela M Brosnahan; Kyongtae T Bae; Douglas Landsittel; Fouad T Chebib; Alan Sl Yu; Vicente E Torres; Peter C Harris
Journal:  JCI Insight       Date:  2020-08-06

5.  Personalized Nanotherapy by Specifically Targeting Cell Organelles To Improve Vascular Hypertension.

Authors:  Rajasekharreddy Pala; Ashraf M Mohieldin; Kiumars Shamloo; Rinzhin T Sherpa; Sarmed H Kathem; Jing Zhou; Zhongyue Luan; Jian-Guo Zheng; Amir Ahsan; Surya M Nauli
Journal:  Nano Lett       Date:  2018-12-26       Impact factor: 11.189

6.  Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?

Authors:  Reem A Mustafa; Alan S L Yu
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-13       Impact factor: 8.237

7.  Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.

Authors:  Timothy L Kline; Panagiotis Korfiatis; Marie E Edwards; Kyongtae T Bae; Alan Yu; Arlene B Chapman; Michal Mrug; Jared J Grantham; Douglas Landsittel; William M Bennett; Bernard F King; Peter C Harris; Vicente E Torres; Bradley J Erickson
Journal:  Kidney Int       Date:  2017-05-20       Impact factor: 10.612

8.  Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Alan S L Yu; Chengli Shen; Douglas P Landsittel; Peter C Harris; Vicente E Torres; Michal Mrug; Kyongtae T Bae; Jared J Grantham; Frederic F Rahbari-Oskoui; Michael F Flessner; William M Bennett; Arlene B Chapman
Journal:  Kidney Int       Date:  2017-12-28       Impact factor: 10.612

9.  Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.

Authors:  A Lianne Messchendorp; Esther Meijer; Folkert W Visser; Gerwin E Engels; Peter Kappert; Monique Losekoot; Dorien J M Peters; Ron T Gansevoort
Journal:  Am J Nephrol       Date:  2019-10-10       Impact factor: 3.754

10.  The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.

Authors:  Emilie Cornec-Le Gall; Fouad T Chebib; Charles D Madsen; Sarah R Senum; Christina M Heyer; Brendan C Lanpher; Marc C Patterson; Robert C Albright; Alan S Yu; Vicente E Torres; Peter C Harris
Journal:  Am J Kidney Dis       Date:  2018-02-01       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.